28th Feb 2007 07:01
Futura Medical PLC28 February 2007 For immediate release 28 February 2007 Futura Medical Plc Launches DermaSys(R) as brand name for proprietary drug delivery technology Futura Medical plc (Futura), the AIM-listed pharmaceutical group that developsinnovative products for the consumer healthcare market, announces the launch ofDermaSys(R) as the brand name for its versatile gel technology for the rapiddelivery of drugs through the skin. The DermaSys(R) technology was originally developed by Futura for use in theCompany's topical treatment for erectile dysfunction, MED2002. Futura iscontinuing its assessment program for DermaSys(R) against a wide range ofgeneric drugs suited to topical delivery where substantial improvements in speedof absorption and permeability across the skin would result in attractivecommercial opportunities. For more information please visit the Futura websiteby clicking on the following link: http://www.futuramedical.co.uk/content/products/delivery_technology.asp DermaSys(R) is a versatile and bespoke technology which can be adapted to suitthe specific active compound being used and the therapeutic indication. Suchtargeted delivery offers an optimised profile in terms of dose, onset time andduration of effect as well as an improved safety profile through lower systemicuptake and the reduced risk of side effects. James Barder, Futura Medical's Chief Executive, said: "We are pleased toannounce the launch of DermaSys(R) as the brand name of our proprietary drugdelivery technology. DermaSys(R) is an important asset within Futura and weintend to continue to exploit its potential." For further information:Futura Medical plcJames Barder, Chief Executive Tel: +44 (0) 1483 685 670mail to: [email protected] www.futuramedical.co.uk Media enquiries:Buchanan CommunicationsMark Court / Rebecca Dietrich Tel: +44 (0) 020 7466 5000 Notes Futura Medical plc Futura Medical is a pharmaceutical group that develops innovative products forthe consumer healthcare market with a strong expertise in sexual health. TheCompany is developing a portfolio of products and its strategy is to licensetheir manufacture and distribution to major pharmaceutical and healthcaregroups. Futura's primary focus is on over-the-counter products with particularappeal to men and women who are reluctant to discuss potentially embarrassingsexual matters with their doctors. Futura is based in Guildford, Surrey, and its shares trade on the AIM market ofthe London Stock Exchange. www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Futura Medical